Elmiron Pigmentary Maculopathy lawsuit settlement criteria
Since the first bellwether trials concluded in 2023, the litigation landscape surrounding Elmiron (pentosan polysulfate sodium) and its link to pigmentary maculopathy has undergone significant transformation. As of early 2026, multidistrict litigation (MDL) proceedings in the District of New Jersey have established clear settlement frameworks that prioritize objective retinal imaging evidence over subjective symptom reports. We are tracking these developments closely because the criteria continue to evolve as new data emerges from ongoing ophthalmologic surveillance programs.
Key Settlement Tiers Defined by the 2024-2025 MDL Bellwether Outcomes
The settlement structure now hinges on three primary factors: cumulative dosage, duration of use, and specific diagnostic findings on spectral-domain optical coherence tomography (SD-OCT). Judge Brian R. Martinotti's pretrial orders in In re: Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation (MDL No. 2873) established that claimants must demonstrate at least two years of continuous Elmiron use with a cumulative dose exceeding 500 grams. The following table summarizes the current settlement tiers as negotiated between plaintiffs' steering committees and Janssen Pharmaceuticals in late 2025:
| Settlement Tier | Minimum Cumulative Dose | Required SD-OCT Findings | Estimated Compensation Range |
|---|---|---|---|
| Tier 1 (Early Stage) | 500-1,000 g | Intraretinal hyper-reflective foci in outer nuclear layer | $75,000 - $150,000 |
| Tier 2 (Moderate) | 1,000-1,500 g | Ellipsoid zone disruption with RPE atrophy | $200,000 - $400,000 |
| Tier 3 (Severe) | 1,500+ g | Choroidal neovascularization or geographic atrophy | $500,000 - $1,200,000 |
These figures represent base compensation before factoring in age-related vision loss comorbidities and the presence of bilateral versus unilateral involvement. We have observed that claimants with pre-existing age-related macular degeneration face additional scrutiny during the causation review process.
Diagnostic Documentation Requirements from the Retina Specialists at Wills Eye Hospital and Bascom Palmer
The most contentious element of the settlement criteria involves the specificity of diagnostic documentation. The MDL's science committee, which includes experts from Wills Eye Hospital and the Bascom Palmer Eye Institute, has mandated that standard fundus photography alone is insufficient. Claimants must submit:
- SD-OCT scans demonstrating characteristic hyper-reflective deposits in the outer retinal layers, distinct from drusen associated with AMD
- Fundus autofluorescence (FAF) imaging showing a unique perifoveal pattern of hyperautofluorescence that correlates with pentosan polysulfate accumulation
- Multifocal electroretinography (mfERG) results confirming reduced macular function in the absence of other known retinal pathologies
- Detailed medication records from pharmacy databases or prescribing physicians verifying uninterrupted Elmiron therapy for interstitial cystitis
We recommend that attorneys coordinate directly with retinal specialists who have published on pentosan polysulfate toxicity, as their expert affidavits carry significantly more weight during the claims review process. The 2025 ruling in Doe v. Janssen established that retrospective diagnosis by a general ophthalmologist without SD-OCT correlation may be deemed insufficient for Tier 2 or Tier 3 compensation.
Statute of Limitations Challenges and the 2026 State-by-State Filing Deadlines
A critical development in 2026 involves the varying statutes of limitations across jurisdictions. While the MDL operates under federal multidistrict procedures, individual state laws govern when plaintiffs must file their claims. We have identified that at least 14 states have two-year discovery rules, meaning patients who stopped taking Elmiron before 2024 may already be time-barred. The following blockquote from the official MDL docket highlights the current judicial stance on this issue:
"The court acknowledges that the latency period between Elmiron exposure and clinically significant vision loss creates unique statute of limitations challenges. However, the discovery rule requires that plaintiffs file within two years of when a reasonably diligent person would have connected their retinal findings to pentosan polysulfate use. For most claimants, this clock began ticking with the FDA's 2020 safety communication or the 2022 American Society of Retina Specialists clinical guidelines." — Order on Motions for Summary Judgment, MDL 2873, January 2026.
Reference: bionovaholding.com | Archive: Web Archive
We urge potential claimants to consult with experienced pharmaceutical litigation attorneys immediately, particularly those in states like California, New York, and Florida where the courts have applied the discovery rule more broadly. The window for filing claims under the current settlement framework is expected to narrow significantly after the third quarter of 2027, when Janssen has indicated it may seek to cap aggregate settlement funds based on actuarial projections of remaining eligible claimants.